Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × infigratinib × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 8 Genitourinary 5 CNS 3 Thoracic 1 Sarcoma 1 Other hematologic neoplasm 1 Head & Neck 1 Gynecologic 1 Dermatologic 1 Breast 1

Conditions

Interventions

pembrolizumab 291 Nivolumab 254 Ipilimumab 228 Cyclophosphamide 178 aldesleukin 134 Interleukin-2 97 fludarabine phosphate 96 fludarabine 77 Temozolomide 73 Dacarbazine 73 trametinib 69 Radiotherapy 69 Vemurafenib 63 dabrafenib 60 Biopsy 59 Radiosurgery 48 Bevacizumab 47 sargramostim 44 Magnetic Resonance Spectroscopy 44 Imiquimod 43 Aminolevulinic Acid 43 Peripheral Blood Stem Cell Transplantation 42 Cisplatin 42 Paclitaxel 41 binimetinib 39 Carboplatin 39 3-ingenyl angelate 39 incomplete Freund's adjuvant 37 Specimen Handling 37 atezolizumab 36

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02159066 2024-03-05

LOGIC-2

Pfizer

Phase 2 Completed

158 enrolled 40 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡